Italia markets closed

Oryzon Genomics S.A. (0RDB.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,1700+0,0350 (+1,64%)
Alla chiusura: 08:59AM BST
Schermo intero
Chiusura precedente2,1350
Aperto2,1700
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,1700 - 2,1700
Intervallo di 52 settimane2,1700 - 2,1700
Volume1
Media VolumeN/D
Capitalizzazione792.859
Beta (5 anni mensile)1,16
Rapporto PE (ttm)N/D
EPS (ttm)-0,0880
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

    At the 10th European Conference on Mental Health (ECMH)Company expects to perform an interim analysis in 1Q23 MADRID, Spain and BOSTON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents initial preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderli

  • GlobeNewswire

    ORYZON to Give Updates on Corporate Progress in September

    H.C. Wainwright Global Investment Conference10th European Conference on Mental HealthSachs Annual Biotech in Europe ForumAnnual RAS-Targeted Drug Development SummitXIX Congress of the Spanish Society of Psychogeriatrics MADRID, Spain and BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its managemen

  • GlobeNewswire

    ORYZON Collaborates with the CMT Research Foundation in the US

    To explore Oryzon’s HDAC6 inhibitors on Charcot-Marie-Tooth diseaseCMTRF to provide funding for in vivo efficacy tests in CMT preclinical model MADRID and BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patien